DNAPrint Files First Provisional Software Patent
SARASOTA, Fla., Dec 2, 2000 (BUSINESS WIRE) -- DNAPrint genomics, Inc. (Pink
Sheets:DNAP) announced today that the company has provisionally filed the first
in what it expects to be a string of patents covering tools and methods for use
within the field of personalized medicine. The provisional application, entitled
Methods and Apparatus for use in Processing Gene Sequence Data, was filed with
the US Patent and Trademark Office on 11/22/00.
Personalized medical products of the near future will use multiple genetic
markers to match patients with drugs that are safe and efficacious. Genetic
concordance or association studies are expected to yield the information
necessary for the construction of these products and a process known as
inferential haplotyping is the preferred process by which these studies are
conducted. Inferential haplotyping is the process of predicting complex genetic
marker combinations in individual patients. At present, determining complex,
haplotype data is not possible using current high-throughput genotyping
methodologies. Further, the process involves several technical and theoretical
limitations which bias it towards all but the most frequent haplotypes in a
population. The scope of the provisional patent announced today, represents the
first in what the company expects to be a series of patents related to
algorithms involved in the process, and describes a tool that is necessary for
building information resources, as well as for using this information to
accurately infer genetic haplotypes from raw genotype data.
The company is using the tools covered in the invention to develop innovative
information (PhenomeSM SNP/Haplotype database) assets that will serve as a
platform for the companies work.
About DNAprint genomics
DNAPrint genomics, Inc. is developing complex genetic analytics and information
resources for next generation personalized medicine. The company's products will
provide practitioners of genomic research and personalized medicine with a
comprehensive system for complex trait dissection and patient classification.
DNAPrint genomics Inc. was founded by a group of scientists with research and
commercial experience in high-level mathematical modeling, programming and
molecular genetics. On November 3, 2000, the company announced that it had filed
its form 8K and expects to be trading on the OTCBB within the next several
weeks. For more information about the company, please visit www.DNAPrint.com
All statements in this press release that are not historical are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act as
amended. Such statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected, including, but not
limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/351-4543
or
Other inquiries
Richard Craig Hall, 941/341-0136
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
-0-
KEYWORD: FLORIDA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
SOFTWARE
*** end of story *** |
